| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/16/2010 | US7662923 Modified vitamin K-dependent polypeptides |
| 02/16/2010 | US7662922 Canola protein isolate compositions |
| 02/16/2010 | US7662921 Methods of treating viral disorders |
| 02/16/2010 | US7662920 Made by inter-molecularly crosslinking the fluorescent protein such as a phycobiliprotein with itself; easier to purify; assay sensitivity; use in labeling and detection of biomolecules; crosslinker such as disuccinimidyl suberate |
| 02/16/2010 | US7662919 Notch-based fusion proteins and uses thereof |
| 02/16/2010 | US7662914 Native chemical ligation with three or more components |
| 02/16/2010 | US7662910 Inhibitors for the soluble epoxide hydrolase |
| 02/16/2010 | US7662798 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| 02/16/2010 | US7662795 Enhancement of adenoviral oncolytic activity by modification of the E1A gene product |
| 02/16/2010 | US7662794 DNA enzyme to inhibit plasminogen activator inhibitor-1 |
| 02/16/2010 | US7662793 Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter |
| 02/16/2010 | US7662792 Modulation of Fas and FasL expression |
| 02/16/2010 | US7662789 Peptide substance restoring myocardium function |
| 02/16/2010 | US7662788 Abuse-resistant amphetamine prodrugs |
| 02/16/2010 | US7662787 lisdexamfetamine, lisdexamfetamine dimesylate and lisdexamfetamine hydrochloride; attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity |
| 02/16/2010 | US7662786 Dolastatin 15 derivatives |
| 02/16/2010 | US7662785 selective high affinity ligand (SHAL), ligands are joined directly or through a linker, binds to a cancer cell bearing an HLA-DR10 surface antigen; for the diagnosis and treatment of various diseases such as cancer |
| 02/16/2010 | US7662784 Method for decreasing body weight using a somatostatin receptor agonist |
| 02/16/2010 | US7662783 Inhibiting angiogenesis, solid tumor growth and metastasis in the tissue of a mammal by administering to the mammal an active agent comprising an angiogenesis-inhibiting amount of a selective antagonist of denatured collagen type-IV |
| 02/16/2010 | US7662782 Melanocortin 1 receptor selective compounds |
| 02/16/2010 | US7662781 Immunopotentiating agent |
| 02/16/2010 | US7662780 Administering hypocretin to obese individuals |
| 02/16/2010 | US7662779 Triazolyl macrocyclic hepatitis C serine protease inhibitors |
| 02/16/2010 | US7662778 a compound containing cyclic tetrapeptide coupled to amide, ester, ketone groups; apoptosis and cell differentiation inducer; cancer metastasis and angiogenesis inhibitor; catalytic hydrogenation, acid treatment, fluoride anion treatment, or hydrolysis for deblocking; coupling cyclic tertrapeptide |
| 02/16/2010 | US7662777 Particularly oral mucositis as a result of chemotherapy or radiotherapy |
| 02/16/2010 | US7662776 Treatment of tumors using short peptides from human chorionic gonadotropin (HCG) |
| 02/16/2010 | US7662775 Method for screening agents for the treatment of diabetes |
| 02/16/2010 | US7662774 Treating syndromes associated with acute or chronic inflammation where activation of Factor VII, Xa and tissue factor expression is involved |
| 02/16/2010 | US7662773 Natriuretic compounds, conjugates, and uses thereof |
| 02/16/2010 | US7662772 Methods for treating congestive heart failure |
| 02/16/2010 | US7662771 Drug delivery; controlled/sustained release |
| 02/16/2010 | US7662770 Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target |
| 02/16/2010 | US7662769 Acetylglucosaminyl transferases; neovascularization inhibitor screening; antibodies; kits |
| 02/16/2010 | US7662768 Transdifferentiation of pancreatic acinar cells |
| 02/16/2010 | US7662641 using the antibodies to detect the presence of the protein; Zven is a human protein expressed in testicular tissue and peripheral blood lymphocytes; stimulate gastrointestinal contractility, gastric emptying, intestinal transit, and treating gastroparesis; may also inhibit Wnt gene; lung tumors |
| 02/16/2010 | US7662633 Method of screening for inhibitors of osteopontin |
| 02/16/2010 | US7662629 Cationic peptide scaffold conjugated to a nuclear targeting peptide through a specified hydrolysis resistant chemical linkage; use in transfection i.e. nonviral gene transfer |
| 02/16/2010 | US7662622 Flea peritrophin nucleic acid molecules |
| 02/16/2010 | US7662620 Stem cell-derived neuron survival factor polypeptides (SDNSF) for use in prevention and treatment of cell proliferative, neurodegenerative and cardiovascular disorders |
| 02/16/2010 | US7662604 Chondroitinase ABC I and methods of production |
| 02/16/2010 | US7662592 in vitro biosynthesis; Lactobacillus, Streptococcus, Enterococcus strains |
| 02/16/2010 | US7662590 Produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins; has anti-hepatitis activity; culturing |
| 02/16/2010 | US7662589 Produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins; has anti-hepatitis activity; culturing |
| 02/16/2010 | US7662585 ErbB4 receptor-specific neuregulin related ligands and uses therefor |
| 02/16/2010 | US7662552 Identifying vision defects associated with mutation in gamma-s-crystallin gene (GRYGS) |
| 02/16/2010 | US7662548 Method of screening for modulators of HIV infection |
| 02/16/2010 | US7662415 Microbially expresses xylanases and their use as feed additives and other uses |
| 02/16/2010 | US7662408 Sustained-release preparations |
| 02/16/2010 | US7662404 Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides |
| 02/16/2010 | US7662403 Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof |
| 02/16/2010 | US7662395 Recombinant virus encoding an antigen of a disease state; second recombinant virus encoding an immunostimulatory molecule with an exogenous immunostimulatory molecule, chemotherapeutic drug, antibiotic, antiviral drug or antifungal drug. |
| 02/16/2010 | US7662393 comprises alkali metal salt, alkaline earth metal salt, and citrate/phosphate buffer; improved stability |
| 02/16/2010 | US7662392 Stromal-Derived Factor-1 (SDF), G-CSF (granulocyte-colony stimulating factor), stimulating vasculogenesis; improves cardiac function |
| 02/16/2010 | US7662391 Polynucleotide sequence for Chalmydia pneumonia; therapy, prevention of Chlamydia infections ; vaccines |
| 02/16/2010 | US7662388 Endogenous peptide and active subfragments thereof |
| 02/16/2010 | US7662386 Administering polypeptide comprising the immunogenic portion of wilms' tumor suppressor gene (wt1); tumor-associated antigen in cancer immunotherapy |
| 02/16/2010 | US7662383 Epitope bound by MAbs A, B, C or D, where MAbs A, B, C and D have given variable domains; chimeric or humanized for side effect reduction; polymerase chain reaction |
| 02/16/2010 | US7662382 Inducible ligand for α1β1 integrin and uses |
| 02/16/2010 | US7662379 Interleukin-10 antibodies |
| 02/16/2010 | US7662374 Dual-specificity antibody having specificity for both an activated erbB2 receptor and erbB1 dimers, without significant affinity for monomeric EGFr that is not activate; specificity of the antibodies is due to their recognition and binding of activation epitopes; diagnosis, imaging and for treating tumor |
| 02/16/2010 | US7662372 Insect inhibitory lipid acyl hydrolases |
| 02/16/2010 | US7662370 Low-toxicity, long-circulating human interferon-alpha PEGylated mutants |
| 02/16/2010 | US7662369 Stabilized interferon compositions |
| 02/16/2010 | US7662368 Method of inducing SHC phosphorylation of inducing the SHC/MAPK pathway by administering a peptide of IL-2 |
| 02/16/2010 | US7662367 Variant tumor necrosis factor protein for use in diagnosis, prevention and treatment of inflammation, autoimmune, nervous system and infectious disorders |
| 02/16/2010 | US7662366 Administering granulocyte colony stimulating factor; treating type 2 diabetes in simple, safe manner |
| 02/16/2010 | CA2371912C Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| 02/16/2010 | CA2223701C Fgf9 as a specific ligand for fgfr3 |
| 02/16/2010 | CA2220433C Il-6 activity inhibitor |
| 02/16/2010 | CA2204254C Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand |
| 02/16/2010 | CA2177612C Nucleic acids encoding a house dust mite allergen, der p iii, and uses therefor |
| 02/16/2010 | CA2154231C Process for the preparation of a c1-esterase inhibitor concentrate (c1-inh) and concentrate thus obtained, for therapeutic uses |
| 02/11/2010 | WO2010017478A2 Pak1 agonists and methods of use |
| 02/11/2010 | WO2010017432A1 Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion |
| 02/11/2010 | WO2010017403A2 Therapeutic compositions, devices and methods for observing treated tissues |
| 02/11/2010 | WO2010017369A2 Macromolecular diffusion and release from self-assembled b-hairpin peptide hydrogels |
| 02/11/2010 | WO2010017290A1 Müllerian inhibiting substance (mis) analogues |
| 02/11/2010 | WO2010017224A2 Methods of treating cognitive impairment |
| 02/11/2010 | WO2010017198A2 Fgfr extracellular domain acidic region muteins |
| 02/11/2010 | WO2010017178A1 Treatment or prevention of hepatitis c with immunomodulator compounds |
| 02/11/2010 | WO2010017152A2 Modulation of toll-like receptor 8 expression by antisense oligonucleotides |
| 02/11/2010 | WO2010017102A2 Methods for intracellular modulation of bone morphogenetic protein signaling |
| 02/11/2010 | WO2010017100A1 Treatment of excess cerumen secretion |
| 02/11/2010 | WO2010016944A2 Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal |
| 02/11/2010 | WO2010016940A2 Analogues of glucose-dependent insulinotropic polypeptide |
| 02/11/2010 | WO2010016938A2 Glucose-dependent insulinotropic polypeptide analogues |
| 02/11/2010 | WO2010016936A1 Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide |
| 02/11/2010 | WO2010016935A2 Truncated analogues of glucose-dependent insulinotropic polypeptide |
| 02/11/2010 | WO2010016766A2 Antibodies recognizing endogenous human lgr5 and/or lgr6 |
| 02/11/2010 | WO2010016590A1 Therapeutic or prophylactic agent for generalized pain syndrome |
| 02/11/2010 | WO2010016525A1 Immunity inducer |
| 02/11/2010 | WO2010015899A2 Novel method to generate meganucleases with altered characteristics |
| 02/11/2010 | WO2010015701A1 Improved bacterial polysaccharide-polypeptide conjugate compositions |
| 02/11/2010 | WO2010015665A2 Compounds and methods |
| 02/11/2010 | WO2010015264A1 L-asparaginase from helicobacter pylori |
| 02/11/2010 | WO2010015098A1 Veterinary pharmaceutical formulation comprising an rna recombinant particle encoding a cu/zn superoxide dismutase protein of ruminant pathogenic bacteria and at least one rna alphavirus belonging to the semliki forest virus family |
| 02/11/2010 | WO2010015090A1 Functionalized pyrrolidines and use thereof as iap inhibitors |
| 02/11/2010 | WO2010015087A1 Method of inducing stem cell differentiation |
| 02/11/2010 | WO2010015036A1 Biological applications of steroid binding domains |
| 02/11/2010 | WO2009136298A3 Compositions and methods for inhibiting shiga toxin and shiga-like toxin |